Establishment Labs (NASDAQ:ESTA) Releases Earnings Results

Key Points

• Revenue exceeded expectations: Establishment Labs reported quarterly revenue of $67.54 million, up 31.7% year over year and above the $65.79 million consensus estimate. However, adjusted EPS was a loss of $0.39, missing estimates by $0.05.
• Growth and profitability improved: U.S. revenue surged 140.9%, Motiva implants surpassed 100,000 units, and management raised full-year revenue guidance to $269 million-$271 million. Gross margin expanded to 70.6%, while adjusted EBITDA turned positive at $3.7 million.
• Near-term risks remain: Management expects seasonal weakness in the third quarter, while Middle East demand has declined because of regional conflict. Shares fell to $79.05, despite analysts maintaining a “Moderate Buy” consensus and an average price target of $98.38.

Establishment Labs (NASDAQ:ESTA - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.05), FiscalAI reports. The firm had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.Establishment Labs's revenue was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.57) EPS.

Here are the key takeaways from Establishment Labs' conference call:

• Positive Sentiment: Q2 revenue rose 31.7% year over year to $67.5 million, led by U.S. revenue growth of 140.9% to $24.7 million. Management raised full-year revenue guidance to $269 million-$271 million.
• Positive Sentiment: U.S. adoption of Motiva continued to accelerate, surpassing 100,000 implants and 2,000 customer accounts in under 21 months. Increasing utilization within existing accounts and growing patient requests for Motiva are supporting momentum.
• Positive Sentiment: The minimally invasive platform generated $12.1 million in Q2 revenue and is expected to approach 15% of full-year revenue. Preservé training exceeded expectations with more than 300 certified U.S. surgeons, while the company expects to train approximately 500 during 2026.
• Positive Sentiment: Profitability and cash generation improved substantially, with gross margin expanding to 70.6% and adjusted EBITDA turning positive at $3.7 million versus a prior-year loss of $8.5 million. Management expects to become free-cash-flow positive in the second half of 2026 and for fiscal 2027, without needing additional equity raises.
• Negative Sentiment: The third quarter is expected to reflect normal seasonal weakness, with the fourth quarter typically strongest. Middle East distributor demand has fallen because of regional conflict and is expected to remain depressed for the rest of the year, although the region represents less than 5% of revenue.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA traded down $12.20 during midday trading on Thursday, reaching $79.05. The company's stock had a trading volume of 1,151,900 shares, compared to its average volume of 554,274. The business's fifty day simple moving average is $86.29 and its 200-day simple moving average is $74.23. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. Establishment Labs has a fifty-two week low of $33.35 and a fifty-two week high of $97.59. The company has a market capitalization of $2.33 billion, a P/E ratio of -53.05 and a beta of 1.07.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ESTA. Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a research note on Thursday. Weiss Ratings reissued a "sell (e+)" rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Mizuho raised their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Needham & Company LLC lifted their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a "buy" rating in a report on Thursday. Finally, Citigroup increased their target price on Establishment Labs from $76.00 to $92.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $98.38.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new position in shares of Establishment Labs during the third quarter worth approximately $34,000. Kestra Advisory Services LLC bought a new position in Establishment Labs in the 4th quarter worth approximately $47,000. Osaic Holdings Inc. lifted its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after buying an additional 1,800 shares in the last quarter. PharVision Advisers LLC bought a new position in Establishment Labs in the 3rd quarter valued at $203,000. Finally, Twinbeech Capital LP bought a new position in Establishment Labs in the 4th quarter valued at $214,000. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source